Extra-gastrointestinal stromal tumor of the pancreas: case report and review of the literature

Table 2 Selected agents investigated in the management of GIST

Author	Year	Pts (n)	Phase study	Treatment	End point	Outcome (% or median)	P value
Demetri et al. [42]	2002	147	II	Imatinib	OR	81.6%
Demetri GD et al. [43]	2006	312	III	Sunitinib/placebo	TTP	27.3 vs. 5.4 weeks	<0.0001
Blanke et al. [44]	2008	746	III	Imatinib 400 mg/	PFS	18 vs. 20 months	0.13
Blanke et al. [44]	2008	746	III	Imatinib 800 mg	OS	55 vs. 51 months	0.83
De Matteo et al. [45]	2009	713	III	Imatinib/placebo	PFS	98% vs. 83%	<0.0001
Dubreuil et al. [46]	2009	30	II	Masitinib	PFS	165.2 weeks
Sawaki et al. [47]	2011	35	II	Nilotinib	PFS	16 weeks
Park et al. [48]	2011	31	II	Sorafenib	PFS	4.9 months
Park et al. [48]	2011	31	II	Sorafenib	OS	9.7 months
Joensuu et al. [49]	2012	400	III	Imatinib 12mo/36mo	RFS & OS	65.6% vs. 47.9%	<0.0001
						92.0% vs. 81.7%	0.019

OR = overall response; OS = overall survival; PFS = progression-free survival; RFS = recurrence-free survival; TTP = time to tumor progression.

ISSN: 1477-7819